HONG KONG — The cyclin-dependent kinase (CDK) 4/6 pathway inhibitor, ribociclib (LEE011, Novartis AG), in combination with Femara (letrozole, Novartis AG), significantly improved progression-free survival (PFS) in postmenopausal Asian women with advanced breast cancer, in a subanalysis of the MONALEESA-2 trial.